Cutibacterium granulosum
Selected indexed studies
- Comparative genomic analyses of Cutibacterium granulosum provide insights into genomic diversity. (Front Microbiol, 2024) [PMID:38304712]
- Propionibacterium (Cutibacterium) granulosum Extracellular DNase BmdE Targeting Propionibacterium (Cutibacterium) acnes Biofilm Matrix, a Novel Inter-Species Competition Mechanism. (Front Cell Infect Microbiol, 2021) [PMID:35155271]
- Cutibacterium modestum sp. nov., isolated from meibum of human meibomian glands, and emended descriptions of Cutibacterium granulosum and Cutibacterium namnetense. (Int J Syst Evol Microbiol, 2020) [PMID:32559834]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Comparative genomic analyses of Cutibacterium granulosum provide insights into genomic diversity. (2024) pubmed
- Propionibacterium (Cutibacterium) granulosum Extracellular DNase BmdE Targeting Propionibacterium (Cutibacterium) acnes Biofilm Matrix, a Novel Inter-Species Competition Mechanism. (2021) pubmed
- Cutibacterium modestum sp. nov., isolated from meibum of human meibomian glands, and emended descriptions of Cutibacterium granulosum and Cutibacterium namnetense. (2020) pubmed
- Integrated analysis of microbiome and metabolome reveals signatures in PDAC tumorigenesis and prognosis. (2024) pubmed
- The Brief Case: A Mixed Cutibacterium Species Positive Valve Culture Hiding a Bartonella Infective Endocarditis. (2023) pubmed
- Fast and Sensitive Multiplex Real-Time Quantitative PCR to Detect Cutibacterium Periprosthetic Joint Infections. (2022) pubmed
- Unravelling the eco-specificity and pathophysiological properties of Cutibacterium species in the light of recent taxonomic changes. (2021) pubmed
- The increasing importance of the gut microbiome in acne vulgaris. (2022) pubmed
- Propionibacterium/Cutibacterium species-related positive samples, identification, clinical and resistance features: a 10-year survey in a French hospital. (2020) pubmed
- Intratumoral Microbiota Correlates with AP-2 Expression: A Pan-Cancer Map with Cohort-Specific Prognostic and Molecular Footprints. (2025) pubmed